CN1640867A - Venlafaxine and its salt preparing method - Google Patents
Venlafaxine and its salt preparing method Download PDFInfo
- Publication number
- CN1640867A CN1640867A CN 200410002726 CN200410002726A CN1640867A CN 1640867 A CN1640867 A CN 1640867A CN 200410002726 CN200410002726 CN 200410002726 CN 200410002726 A CN200410002726 A CN 200410002726A CN 1640867 A CN1640867 A CN 1640867A
- Authority
- CN
- China
- Prior art keywords
- reaction
- venlafaxin
- acid
- solvent
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to the preparation process of Venlafaxine and its salt. The preparation process includes the condensation reaction of p-methoxy benzyl cyanide as material and acetophenone, direct acidification of reacted mixture and filtering to obtain coarse polymer; purification to obtain pure intermediate; Raney Ni catalyzed reduction or Red-Al reduction of the intermediate into amine; methylation of the amine to obtain Venlafaxine; and reaction between Venlafaxine with acid to obtain salt of Venlafaxine.
Description
Technical field
The present invention relates to the preparation method of compound venlafaxin (1-[2-(dimethylin)-1-(4-p-methoxy-phenyl) ethyl] hexalin) and salt thereof, belong to chemical industry and chemical field of medicaments.
Background technology
Venlafaxin (claiming Venlafaxine again, Venlafaxine, 1) is 1-[2-(dimethylin)-1-(4-p-methoxy-phenyl) ethyl] common name of hexalin, its structural formula is:
Venlafaxin is a kind of novel antidepressant that is different from unique chemical structure of having of other thymoleptic and neuropharmacology effect.It brings into play antidepressant effect by the recovery of remarkable inhibition serotonin and norepinephrine, and to monoamine oxidase unrestraint effect.Acceptors such as this product and cholinergic, histaminergic and adrenergic do not have avidity, thereby do not have these acceptor mesomeric related side effects yet, as calmness, dry, constipation, uroschesis and blurred vision etc.Through a large amount of pharmacological evaluation and clinical application, venlafaxin has shown the pharmacological treatment effect similar to traditional tricyclic antidepressant, has advantages such as rapid-action, that untoward reaction is few again, is a kind of rising thymoleptic.Its preparation method mainly be starting raw material and n-Butyl Lithium with the PARA METHOXY PHENYL ACETONITRILE-70 ℃ down after the reaction again with the pimelinketone condensation, then with Lithium Aluminium Hydride or rhodium/aluminum oxide (Rh/Al
2O
3) reduction etc., owing under extremely low temperature, operate, and need absolute anhydrous and oxygen-free tetrahydrofuran (THF) (THF) be solvent, above-mentioned condition makes venlafaxin be difficult to realize large-scale industrial production; Because used n-Butyl Lithium is difficult to industrial preparation, rhodium/price of aluminium oxide costliness, make that the synthetic cost of venlafaxin is higher again.
Summary of the invention
In view of the defective that present venlafaxin synthetic method exists, the invention provides a kind of easy and simple to handle, cost is low, yield is high, reaction conditions is easy to realize and be suitable for the suitability for industrialized production venlafaxin preparation method.The present invention also provides the preparation method of the salt of the venlafaxin with above-mentioned advantage.
Venlafaxin preparation method of the present invention comprises the steps:
A. the condensation reaction of PARA METHOXY PHENYL ACETONITRILE 2 and pimelinketone 3; It is alkali that hydride or alcoholization sodium or potassium are adopted in this reaction, is solvent with alkanes, aromatics or ethers, obtains condenses 4 crude products, and purifying crude is obtained pure product 4;
B. condenses 4 is through Raney Ni catalytic reduction or Red-Al (Na[H
2Al (OCH
2CH
2OMe)
2]) reduction, obtain intermediate amine 5;
C. the amino with intermediate amine 5 carries out methylation reaction, obtains venlafaxin 1.
If the salt 6 of preparation venlafaxin, then need venlafaxin and acid reacted and make this salt.
Above-mentioned reaction scheme is as follows:
Step a of the present invention is under the effect of alkali, in solvent, make PARA METHOXY PHENYL ACETONITRILE 2 and pimelinketone 3 that condensation reaction takes place, temperature of reaction is controlled to be made as-10 ℃～25 ℃, reaction times was generally 6～26 hours, after reacting completely, acidified reaction mixture filters and obtains thick condenses, recrystallization obtains pure condenses 4, and recrystallization solvent is one or more in toluene, benzene, the dimethylbenzene.The alkali that this reaction is adopted is hydride or alcoholization sodium/potassium, and it comprises potassium hydride KH, sodium hydride, hydrolith, potassium tert.-butoxide, sodium methylate or sodium ethylate etc.The solvent that this reaction is adopted is alkanes, aromatics or ethers, as in normal hexane, Skellysolve A, sherwood oil, benzene, toluene, tetrahydrofuran (THF) or the ether one or more.
Step b is in solvent, through Raney Ni catalytic reduction, condenses 4 is reduced to amine 5.Temperature of reaction is controlled to be made as 10 ℃～45 ℃, and the reaction times was generally 4～24 hours.The solvent that this reaction is adopted is one or more in methyl alcohol, ethanol, ethyl acetate or the acetate.This step also can be to adopt Red-Al to reduce, and obtains amine 5.Temperature of reaction is controlled to be made as 10 ℃～45 ℃, and the reaction times was generally 1～15 hour.The solvent that this reaction is adopted is ether, diethylene glycol dimethyl ether, tetrahydrofuran (THF) or 1, one or more in the 4-dioxane.
Step c is the methylation reaction of amine 5, and product is a venlafaxin 1.The methylation reaction that the methylation reaction of this step methylation reaction that can be amine 5 carry out with formaldehyde and formic acid mixtures and amine 5 and methyl halide such as methyl iodide or monobromethane carry out.
The reaction of salt of preparation venlafaxin is that the venlafaxin of step c gained and acid-respons are made.The acid group of this reaction can be haloid acid example hydrochloric acid, Hydrogen bromide, hydroiodic acid HI or nitric acid, sulfuric acid, Citric Acid, toxilic acid, tartrate etc. according to needs.Adopt the salt crude product of the method purifying gained of recrystallization, recrystallization solvent is one or more in methyl alcohol, ethanol, the ethyl acetate.
The present invention has got rid of reagent such as expensive n-Butyl Lithium, rhodium/aluminum oxide, exempted the harsh reaction conditions that absolute anhydrous and oxygen-free tetrahydrofuran (THF) is a solvent, got rid of condition of ultralow temperature, make operation easy, work simplification, cost reduce, and overall yield of reaction also improves greatly simultaneously, and yield is 60%-70%, be higher than the yield of prior art 25%, be suitable for suitability for industrialized production.
Embodiment
Further elaborate preparation method of the present invention by following experimental example.
Embodiment 1:1-[cyano group-(4-methoxyphenyl) methyl] preparation of hexalin 4:
Under-10--5 ℃, in 5 liters of three mouthfuls of round-bottomed flasks, drop into sodium hydride (44.0 grams, 60% is scattered in the mineral oil), 1000 milliliters of toluene, stir and drip PARA METHOXY PHENYL ACETONITRILE 2 (147 gram) down, finish and continue to stir 2.0 hours, the back drips pimelinketone 3 (160 gram), stir and slowly be warming up to room temperature after 2.0 hours, the TLC monitoring is to reacting completely the ice-water bath cooling, regulate pH value to 6.0 with 10% dilute hydrochloric acid, obtain a large amount of white solids, behind the filtration drying, use the toluene recrystallization, get 1-[cyano group-(4-methoxyphenyl) methyl] hexalin 4 (210.7 grams, 86%).
Embodiment 2:1-[cyano group-(4-methoxyphenyl) methyl] preparation of hexalin 4:
Under 0 ℃, in 5 liters of three mouthfuls of round-bottomed flasks, drop into 1000 milliliters of potassium tert.-butoxide (136 gram), tetrahydrofuran (THF)s, stir and drip PARA METHOXY PHENYL ACETONITRILE 2 (147 gram) down, finish and continue to stir 2.0 hours, the back drips pimelinketone 3 (160 gram), stir and slowly be warming up to room temperature after 2.0 hours, the TLC monitoring is to reacting completely, the ice-water bath cooling is regulated pH value to 6.0 with 10% dilute hydrochloric acid, obtains a large amount of white solids, behind the filtration drying, use the benzene recrystallization, get 1-[cyano group-(4-methoxyphenyl) methyl] hexalin 4 (200 grams, 82%).
Embodiment 3:1-[cyano group-(4-methoxyphenyl) methyl] preparation of hexalin 4:
Under 0 ℃, in 5 liters of three mouthfuls of round-bottomed flasks, drop into 1000 milliliters of potassium tert.-butoxide (136 gram), normal hexanes, stir and drip PARA METHOXY PHENYL ACETONITRILE 2 (147 gram) down, finish and continue to stir 2.0 hours, the back drips pimelinketone 3 (160 gram), stir and slowly be warming up to room temperature after 2.0 hours, the TLC monitoring is to reacting completely, the ice-water bath cooling is regulated pH value to 6.0 with 10% dilute hydrochloric acid, obtains a large amount of white solids, behind the filtration drying, use the toluene recrystallization, get 1-[cyano group-(4-methoxyphenyl) methyl] hexalin 4 (186.2 grams, 76%).
Embodiment 4:1-[cyano group-(4-methoxyphenyl) methyl] preparation of hexalin 4:
Under 0 ℃, in 5 liters of three mouthfuls of round-bottomed flasks, drop into 1000 milliliters of sodium methylate (99 gram), tetrahydrofuran (THF)s, 200 milliliters of normal hexanes, stir and drip PARA METHOXY PHENYL ACETONITRILE 2 (147 gram) down, finish and continue to stir 2.0 hours, the back drips pimelinketone 3 (160 gram), stir and slowly be warming up to room temperature after 2.0 hours, the TLC monitoring is to reacting completely the ice-water bath cooling, regulate pH value to 6.0 with 10% dilute hydrochloric acid, obtain a large amount of white solids, behind the filtration drying, use the benzene recrystallization, get 1-[cyano group-(4-methoxyphenyl) methyl] hexalin 4 (178 grams, 73%).
Embodiment 5:1-[cyano group-(4-methoxyphenyl) methyl] preparation of hexalin 4:
Under-10--5 ℃, in 5 liters of three mouthfuls of round-bottomed flasks, drop into sodium hydride (44.0 grams, 60% is scattered in the mineral oil), 1000 milliliters of toluene, 400 milliliters of sherwood oils, stir and drip PARA METHOXY PHENYL ACETONITRILE 2 (147 gram) down, finish and continue to stir 2.0 hours, the back drips pimelinketone 3 (160 gram), stir and slowly be warming up to room temperature after 2.0 hours, the TLC monitoring is to reacting completely the ice-water bath cooling, regulate pH value to 6.0 with 10% dilute hydrochloric acid, obtain a large amount of white solids, behind the filtration drying, use the toluene recrystallization, get 1-[cyano group-(4-methoxyphenyl) methyl] hexalin 4 (176.4 grams, 72%).
Embodiment 6:1-[2-amino-1-(4-methoxyphenyl) ethyl] preparation of hexalin 5:
With 1-[cyano group-(4-methoxyphenyl) methyl] hexalin 4 (210.7 gram) is dissolved in 1 liter of methyl alcohol, adds Raney Ni (100 gram), vigorous stirring, successive reaction is 15 hours under room temperature, filters, after filtrate decompression concentrates, oily matter 5 (184.2 grams, 86%).
Embodiment 7:1-[2-amino-1-(4-methoxyphenyl) ethyl] preparation of hexalin 5:
With 1-[cyano group-(4-methoxyphenyl) methyl] hexalin 4 (210.7 gram) is dissolved in 1 liter of ethyl acetate, adds Raney Ni (100 gram), vigorous stirring, in 45 ℃ of following successive reactions 8 hours, filter, after filtrate decompression concentrates, get oily matter 5 (192.8 grams, 90%).
Embodiment 8:1-[2-amino-1-(4-methoxyphenyl) ethyl] preparation of hexalin 5:
With 1-[cyano group-(4-methoxyphenyl) methyl] hexalin 4 (210.7 gram) is dissolved in 1 liter of tetrahydrofuran (THF), and the frozen water cooling is added dropwise to Red-Al (Na[H under stirring
2Al (OCH
2CH
2OMe)
2]) (1000 gram), vigorous stirring, successive reaction is 6 hours under room temperature, and the frozen water cooling drips saturated aqueous ammonium chloride (500 milliliters) down, and extracted with diethyl ether behind the concentrating under reduced pressure, gets oily matter 5 (197.1 grams, 92%).
Embodiment 9:1-[2-amino-1-(4-methoxyphenyl) ethyl] preparation of hexalin 5:
With 1-[cyano group-(4-methoxyphenyl) methyl] hexalin 4 (210.7 gram) is dissolved in 1 liter of ether, the frozen water cooling, be added dropwise to Red-Al (1000 gram) under stirring, vigorous stirring, reflux, successive reaction 5 hours, the frozen water cooling drips saturated aqueous ammonium chloride (500 milliliters) down, and extracted with diethyl ether is behind the concentrating under reduced pressure, get oily matter 5 (192.8 grams, 90%).
Embodiment 10: the preparation of venlafaxin 1:
1-[2-amino-1-(4-methoxyphenyl) ethyl] hexalin 5 (130 gram), methyl iodide (160 gram), tetrahydrofuran (THF) (1000 milliliters) stir together and spend the night.Decompression is concentrated into 450 milliliters with reaction system down, adds 2000 ml waters then, regulates pH value to 2.0, removes red impurity with ethyl acetate extraction.Water layer is regulated pH value to 12.0 with the 50%NaOH aqueous solution, uses ethyl acetate extraction then, behind the anhydrous magnesium sulfate drying, obtains 111 gram venlafaxins 1 behind the concentrating under reduced pressure.Mp＝102-104℃。
Embodiment 11: the preparation of venlafaxin 1:
1-[2-amino-1-(4-methoxyphenyl) ethyl] hexalin 5 (120 gram), 33% formalin (125 milliliters), 88% formic acid (165 milliliters) and water (1200 milliliters) stirs together and spends the night.Decompression is concentrated into 450 milliliters with reaction system down, adds 2000 ml waters then, regulates pH value to 2.0, removes red impurity with ethyl acetate extraction.Water layer is regulated pH value to 12.0 with the 50%NaOH aqueous solution, uses ethyl acetate extraction then, behind the anhydrous magnesium sulfate drying, obtains 116 gram venlafaxins 1 behind the concentrating under reduced pressure.
Embodiment 12: the preparation of venlafaxin hydrochloride 6:
The 116 gram venlafaxins that embodiment 8 is made are dissolved in 500 milliliters of ethyl acetate, feed hydrogen chloride gas, obtain 126 gram venlafaxin hydrochlorides, use the methanol/ethyl acetate recrystallization, get the pure venlafaxin hydrochloride of 108 grams.Mp＝215-217℃。Ultimate analysis C
17H
28NO
2Cl, measured value (%): C65.09, H 9.31, and N 4.25; Calculated value (%): C 65.05, and H 8.99, and N 4.46.
1H NMR (DMSO-d
6) δ (ppm): 7.41 (4 H, q, phenyl ring); 3.86 (3 H, s, OCH
3); 3.56 (2 H, d, CH
2N); 3.05 (1 H, m, CH-C-N); 2.62 (6 H, d, N-(CH
3)
2); 1.36 (10 H, m, 5 * CH
2).
IR(KBr，cm
-1)：3350，2950，2910。MS(m/z)：58(100％)，134(18％)，91(5％)，119(4％)，179(3％)。FAB-MS(m/z)：278(M
++1，100％)。
Embodiment 13: the preparation of venlafaxin hydrobromate 6:
The 145 gram venlafaxins that embodiment 8 is made are dissolved in 500 ml methanol, drip Hydrogen bromide 130 grams, the frozen water cooling, in system, add 500 milliliters of ethyl acetate, leave standstill, obtain 126 gram venlafaxin hydrochlorides, use the methanol/ethyl acetate recrystallization, get the pure venlafaxin hydrobromate of 112 grams.
Embodiment 14: the preparation of venlafaxin tartrate 6:
The 145 gram venlafaxins that embodiment 8 is made are dissolved in 500 milliliters of ethyl acetate, add tartrate 80 grams, room temperature reaction 16 hours, filter 200 gram venlafaxin tartrate, use the methanol/ethyl acetate recrystallization, 168 restrain pure venlafaxin tartrate.
Claims (10)
1. the preparation method of a venlafaxin is characterized in that, this method may further comprise the steps:
The condensation reaction of step a. PARA METHOXY PHENYL ACETONITRILE and pimelinketone; It is alkali that hydride or alcoholization sodium/potassium are adopted in this reaction, is solvent with alkanes, aromatics or ethers, obtains condenses;
Step b. condenses obtains intermediate amine through Raney Ni or Red-Al reduction;
Step c obtains venlafaxin with the amino methylization of intermediate amine.
2. the method for claim 1 is characterized in that, the alkali among the step a is potassium hydride KH, sodium hydride, hydrolith, potassium tert.-butoxide, sodium methylate or sodium ethylate.
3, the method for claim 1 is characterized in that, the solvent among the step a is one or more in normal hexane, Skellysolve A, sherwood oil, benzene, toluene, tetrahydrofuran (THF) or the ether.
4. the method for claim 1 is characterized in that, the temperature of reaction of step a is-10 ℃-25 ℃, and the reaction times is 6-26 hour.
5. the method for claim 1 is characterized in that, the purifying of condenses adopts the method for recrystallization among the step a, and recrystallization solvent is toluene, benzene, dimethylbenzene.
6. the method for claim 1 is characterized in that, in the Raney of step b Ni catalytic reduction, solvent is one or more in methyl alcohol, ethanol, ethyl acetate or the acetate, and temperature of reaction is 10 ℃-45 ℃, and the reaction times is 4-24 hour.
7. the method for claim 1 is characterized in that, in the Red-Al of step b reduction, solvent is ether, diethylene glycol dimethyl ether, tetrahydrofuran (THF) or 1, in the 4-dioxane one or more, temperature of reaction are 10 ℃-45 ℃, and the reaction times is 1-15 hour.
8. the method for claim 1 is characterized in that, the methylation reaction of step c comprises the methylation reaction that methylates or carry out with haloalkane such as methyl iodide, monobromethane with formaldehyde and formic acid mixtures.
9. the preparation method of the salt of a venlafaxin is characterized in that, venlafaxin and the acid-respons of this method for making by either party's method among the claim 1-8, and make the salt of venlafaxin.
10. method as claimed in claim 9 is characterized in that, described acid is hydrochloric acid, Hydrogen bromide, hydroiodic acid HI, nitric acid, sulfuric acid, Citric Acid, toxilic acid or tartrate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410002726 CN1266116C (en) | 2004-01-19 | 2004-01-19 | Venlafaxine and its salt preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410002726 CN1266116C (en) | 2004-01-19 | 2004-01-19 | Venlafaxine and its salt preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1640867A true CN1640867A (en) | 2005-07-20 |
| CN1266116C CN1266116C (en) | 2006-07-26 |
Family
ID=34867446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410002726 Expired - Fee Related CN1266116C (en) | 2004-01-19 | 2004-01-19 | Venlafaxine and its salt preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1266116C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007047972A3 (en) * | 2005-10-19 | 2007-06-21 | Teva Pharma | Process for the preparation of highly pure 1-[2-dimethylamino-(4-methoxyphenyl) ethyl]cyclohexanol hydrochloride |
-
2004
- 2004-01-19 CN CN 200410002726 patent/CN1266116C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007047972A3 (en) * | 2005-10-19 | 2007-06-21 | Teva Pharma | Process for the preparation of highly pure 1-[2-dimethylamino-(4-methoxyphenyl) ethyl]cyclohexanol hydrochloride |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1266116C (en) | 2006-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1699331A (en) | Process for the synthesis of (is)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane and uses thereof | |
| CN1293048C (en) | New process for the synthesis of (7-methoxy-3,4-dihydro-1-naphthalenyl)acetonitrile and its application in the synthesis of agomelatine | |
| CN1680296A (en) | New process for the synthesis of (7-methoxy-1-naphthyl)acetonitrile and application in the synthesis of agomelatine | |
| CN1765872A (en) | 2-amido-2-[2-(4-alkylphenyl)ethyl]-1,3-methyl glycol preparation method | |
| CN101041622A (en) | Preparation method of memantine salt | |
| CN103664677A (en) | Asymmetric synthesis method of (R,R)-formoterol tartrate | |
| CN1990461A (en) | Industrial preparation method for 3-amino-2, 2-dimethyl propionamide | |
| US6350912B1 (en) | One pot process for the preparation of 1-[2-dimethylamino-(4-methoxyphenyl)-ethyl]cyclohexanol | |
| CN1144779C (en) | Process for preparing alkylphenylethyl aminopropanediol and intermediate obtained therein | |
| CN1121381C (en) | Novel process for preparing ketimine | |
| CN101445462B (en) | Method for preparing tolterodine and tartrate thereof | |
| CN1266116C (en) | Venlafaxine and its salt preparing method | |
| CN110981901B (en) | Purification method of amino-terminated siloxane | |
| CN1173928C (en) | Process for preparing (1R,2S,4R)-(-)-2-[(2'-{N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1] heptane and pharmaceutically acceptable acid addition salts thereof | |
| CN101704755A (en) | Method for preparing p-tert-butylbenzylamine | |
| CN105646261A (en) | Tetracaine preparation method | |
| CN1876621A (en) | Novel process for preparing acetamino diethyl malonate | |
| CN116143658A (en) | Method for simultaneously preparing tripropylacetonitrile, tripropylamide and tripropylacetic acid | |
| CN102199098A (en) | New synthesis method and application of (R)-N-benzyl-1-(4-methoxyphenyl)-2-propylamine | |
| CN101037405A (en) | Preparation method of aniline derivative containing 2-hydroxyethylsulfonyl | |
| CN112194585B (en) | Synthetic method of bromhexine hydrochloride | |
| CN111704577A (en) | Preparation method of cinacalcet hydrochloride | |
| CN101265201B (en) | Method for synthesizing tramadol hydrochloride | |
| CN1626504A (en) | Method for preparing Tolterodine and tartrate | |
| US6689913B2 (en) | Process for preparing terbinafine and HCI salt thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060726 Termination date: 20210119 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |